6. DOCID:27314 SCORE: 0.0019336054580768DOCNO: 9633320OWNER: NLMSTATUS: MEDLINEDESCRIPTOR: Indians, North AmericanQUALIFIER: organization & administrationQUALIFIER: ethnologyQUALIFIER: prevention & controlAUTHOR: H F Clarke HFAUTHOR: R Joseph RAUTHOR: M Deschamps MAUTHOR: T G Hislop TGAUTHOR: P R Band PRAUTHOR: R Atleo RAFFILIATION: Registered Nurses Association, British Columbia, Vancouver.PUBTYPE: Journal ArticleJOURNALTITLE: The Canadian nurse. COUNTRY: CANADATITLE: Reducing cervical cancer among First Nations women.PUBDATE: 19980301
First Nations women in British Columbia have a four to six times higher mortality rate from cancer of the cervix than do women in the general population. Their participation in the provincial Cervical Cytology Screening Program (CCSP) is less regular and less frequent than other women in B.C. Likewise, they have more difficulty in obtaining culturally suitable health care services from respectful and consistent professionals. These issues should be of critical concern to nurses, as nurses provide the majority of health services to First Nations people.

8. DOCID:27949 SCORE: 0.00193014068563524DOCNO: 9818227OWNER: NLMSTATUS: MEDLINEQUALIFIER: pathologyQUALIFIER: pathologyQUALIFIER: pathologyQUALIFIER: pathologyAUTHOR: D L Page DLAUTHOR: J F Simpson JFAFFILIATION: Division of Anatomic Pathology, Vanderbilt University Medical Center, Medical Center North, Nashville, TN 37232, USA.PUBTYPE: Journal ArticlePUBTYPE: ReviewJOURNALTITLE: Current opinion in oncology. COUNTRY: UNITED STATESTITLE: Pathology of preinvasive and excellent prognosis breast cancer.PUBDATE: 19981101
Our review of recent developments in breast cancer involving the evaluation of patients' tissues is aimed at indicators of increased cancer risk (i.e., the atypical hyperplasias) and lesions without metastatic capacity at time of detection, but those lesions with sufficient risk of attaining metastasis that treatment is mandated (i.e., the ductal carcinomas in situ). We also include invasive lesions with little capacity for metastatic behavior, and highlight the histologic criteria for their recognition, as well as their biologic and clinical characterization. Also discussed are advances in the understanding of diagnostic techniques, particularly core needle biopsy.

9. DOCID:27609 SCORE: 0.00192604700735708DOCNO: 9800117OWNER: NLMSTATUS: MEDLINEDESCRIPTOR: Health BehaviorQUALIFIER: prevention & controlAUTHOR: F Baker FAFFILIATION: Behavioral Research Center, American Cancer Society, Atlanta, GA 30329-4251, USA.PUBTYPE: Journal ArticlePUBTYPE: ReviewJOURNALTITLE: Current opinion in oncology. COUNTRY: UNITED STATESTITLE: Behavioral science applied to cancer screening.PUBDATE: 19980901
Behavioral science has played an important role in gaining an understanding of behavior related to use of cancer screening; however, thus far this role has been limited mainly to breast and cervical cancer screening. Progress has been made recently in identifying barriers to cancer screening in underserved populations, the role of provider behavior in promoting screening adherence, and in beginning to understand behavioral issues related to genetic susceptibility. Research based on behavioral science theory is increasing, and there is need for more of this type of theory-based research focused on screening for other types of cancer in addition to breast and cervical screening.

10. DOCID:27630 SCORE: 0.00192604604498341DOCNO: 9932085OWNER: NLMSTATUS: MEDLINEDESCRIPTOR: TaxoidsQUALIFIER: therapeutic useQUALIFIER: drug therapyAUTHOR: C Couteau CAUTHOR: J P Armand JPAFFILIATION: Service d'oncologie médicale, hôpital Tenon, Paris, France.PUBTYPE: Journal ArticlePUBTYPE: ReviewJOURNALTITLE: Bulletin du cancer.COUNTRY: FRANCETITLE: [Irinotecan-containing combinations in solid tumors, except colonic carcinomas]PUBDATE: 19981201
Irinotecan is a new topoisomerase I inhibitor. It has demonstrated antitumor activity in solid tumors, independently of the histologic type, and in squamous cervical carcinoma. Its original mechanism of action offers the possibility to combine it with other drugs. In vitro and in vivo studies have demonstrated synergistic activity between irinotecan, cisplatin and etoposide. This article reviews the main published phases I and II studies with irinotecan. The limiting toxicity of combination schedules in neutropenia. The best results were obtained with the association cisplatin-irinotecan in lung cancer. For the combination etoposide-irinotecan the best schedule of administration remains to be determined.

12. DOCID:27520 SCORE: 0.00185891381459834DOCNO: 9890695OWNER: NLMSTATUS: MEDLINEQUALIFIER: economicsQUALIFIER: economicsQUALIFIER: methodsQUALIFIER: methodsAUTHOR: B E Hillner BEAFFILIATION: Department of Internal Medicine and Massey Cancer Center, Virginia Commonwealth University Richmond, 23298, USA.PUBTYPE: Journal ArticlePUBTYPE: ReviewJOURNALTITLE: Anti-cancer drugs.COUNTRY: ENGLANDTITLE: Review of cost-effectiveness assessments of chemotherapy in adjuvant and advanced breast cancer.PUBDATE: 19981101
Economic assessments of treatment alternatives in breast cancer have been predominantly ones addressing the role and type of adjuvant therapy. These assessments have shown that the effectiveness of the intervention drives the cost-effectiveness results. Other key factors were the relative risk of recurrence, the time frame considered and only minimally the costs of the intervention. Assessments in advanced breast cancer are few in parallel with the limited number of phase III trials. Future assessments should address neoadjuvant therapy, high-dose adjuvant therapy and agents that alter disease associated complications agents such as biphosphonates.

13. DOCID:27514 SCORE: 0.00185891271883549DOCNO: 9516075OWNER: NLMSTATUS: MEDLINEQUALIFIER: pathologyQUALIFIER: physiologyAUTHOR: D Yee DAFFILIATION: University of Texas Health Science Center at San Antonio, 78284-7884, USA. yeed@uthscsa.eduPUBTYPE: Journal ArticleJOURNALTITLE: Breast cancer research and treatment. COUNTRY: NETHERLANDSTITLE: The insulin-like growth factors and breast cancer--revisited.PUBDATE: 19980201
In 1992, a special issue of Breast Cancer Research and Treatment was devoted to the insulin-like growth factors and breast cancer. In that issue, identification of the key components of the IGF system was reviewed and their potential role in breast cancer growth was described. In this issue, we revisit the IGF system with particular attention to data that further supports their role in the growth regulation of breast cancer. Several new facets of the IGF system are described, and several laboratories have more clearly defined how each individual component of the IGF system may influence breast cancer biology.

14. DOCID:27989 SCORE: 0.0018396073545297DOCNO: 10482188OWNER: NLMSTATUS: MEDLINEDESCRIPTOR: Gene TherapyQUALIFIER: therapyAUTHOR: D Hrouda DAUTHOR: M Perry MAUTHOR: A G Dalgleish AGAFFILIATION: Department of Oncology, St George's Hospital Medical School, London, UK.PUBTYPE: Journal ArticlePUBTYPE: ReviewJOURNALTITLE: Seminars in oncology. COUNTRY: UNITED STATESTITLE: Gene therapy for prostate cancer.PUBDATE: 19990801
Prostate cancer is one of the leading causes of cancer deaths in the western hemisphere. A number of different gene therapy strategies are currently being evaluated. The ex vivo and many of the in vivo therapies involve stimulating a specific antitumor immune response. Autologous vaccines involving interleukin-2 (IL-2)- or granulocyte-macrophage colony-stimulating factor (GM-CSF)-transduced whole tumor cells showed great promise in animal models. Clinical trials of these and other vaccine strategies are underway. In vivo gene therapies involving the replacement of mutant tumor-suppressor genes, antisense strategies, and the insertion of suicide genes are also being evaluated in prostate cancer.